3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Prostatic Neoplasms
18
Neoplasms
18
Breast Neoplasms
16
Colorectal Neoplasms
12
Carcinoma, Non-Small-Cell Lung
11
Lung Neoplasms
10
Urinary Bladder Neoplasms
6
Squamous Cell Carcinoma of Head and Neck
6
Hematopoietic and Lymphatic System Neoplasm
6
Hematologic Neoplasms
6
Ovarian Neoplasms
5
Neoplasm Metastasis
5
Triple Negative Breast Neoplasms
4
Leukemia, Myeloid, Acute
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Pancreatic Neoplasms
3
Multiple Myeloma
3
Mouth Neoplasms
3
Hematopoietic and Lymphoid System Neoplasm
3
Head and Neck Neoplasms
3
Fallopian Tube Neoplasms
3
Carcinoma, Renal Cell
3
Sarcoma
2
Radiodermatitis
2
Peritoneal Neoplasms
2
Pathologic Complete Response
2
Parotid Neoplasms
2
Motor Activity
2
Melanoma
2
Malignant Solid Neoplasm
2
Interventions
Temozolomide
3
Cyclophosphamide
3
Etoposide
2
ibrutinib
1
gallium Ga 68 dotatate
1
fludarabine
1
etoposide phosphate
1
belzutifan
1
Zoledronic Acid
1
Vincristine
1
Thiotepa
1
Tamoxifen
1
Standard of Care
1
Radiotherapy
1
ONC206
1
Nivolumab
1
Mesna
1
Isotretinoin
1
Hydrocortisone
1
Granulocyte Colony-Stimulating Factor
1
Filgrastim
1
Eflornithine
1
Drug Therapy
1
Cisplatin
1
Celecoxib
1
Carboplatin
1
Blood Specimen Collection
1
Automobiles
1
1-methyltryptophan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Neuroectodermal Tumors, Primitive
×
Standard of Care
×
Clear all
NCT06861244
2026-04-23
PNOC031
University of California, San Francisco
Phase 2
Recruiting
70 enrolled